Aktienanalyse zu Talphera Inc (TLPH)

KI-Analyse of Talphera Inc (TLPH)

Verkaufen

Talphera Inc is not a good buy right now due to its current price of $1.01 and a very low RSI of 22.51, indicating oversold conditions. The company has reported significant losses, with a net income of -4.43 million USD in Q3 2025 and a forward P/E ratio of 1.02, which is unusually low but reflects the company's ongoing financial struggles. Although analysts have a price target of $3, the stock has decreased by 28.37% over the past year, and the recent performance shows a 5-day change of -5.61%. The main risk is the company's high net loss and reliance on future financing, as indicated by a cash position decrease from $21.1 million to $17.1 million in just a few months, which raises concerns about its operational sustainability.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Talphera Inc (TLPH) beträgt 1.02, verglichen mit dem 5-Jahres-Durchschnitt von -0.85.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

-0.85

Aktuelles P/E

1.02

Überbewertet

0.50

Unterbewertet

-2.19

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

-0.32

Aktuelles EV/EBITDA

-0.01

Überbewertet

0.83

Unterbewertet

-1.48

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

507.28

Aktuelles P/S

121.93

Überbewertet

2323.26

Unterbewertet

-1308.69

Alphio-AI-Kursszenarien für TLPH

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%TLPH

$0.50

Szenariopreis

B

Basis

Basis · 50%TLPH

$0.49

Szenariopreis

B

Bärisch

Bärisch · 25%TLPH

$0.40

Szenariopreis

TLPH FAQ – beantwortet von Alphio AI

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Talphera Inc is not a good buy right now due to its current price of $1.01 and a very low RSI of 22.51, indicating oversold conditions. The company has reported significant losses, with a net income of -4.43 million USD in Q3 2025 and a forward P/E ratio of 1.02, which is unusually low but reflects the company's ongoing financial struggles. Although analysts have a price target of $3, the stock has decreased by 28.37% over the past year, and the recent performance shows a 5-day change of -5.61%. The main risk is the company's high net loss and reliance on future financing, as indicated by a cash position decrease from $21.1 million to $17.1 million in just a few months, which raises concerns about its operational sustainability.